1 / 9

Tessa Mattholie, European Liaison Officer, Brussels

Tessa Mattholie, European Liaison Officer, Brussels. IPM Mission. IPM’s mission is to prevent HIV transmission by accelerating the development and access of safe and effective microbicides for use by women in developing countries. 1. Assess and fund across the microbicide portfolio.

wayne-neal
Download Presentation

Tessa Mattholie, European Liaison Officer, Brussels

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tessa Mattholie, European Liaison Officer, Brussels

  2. IPM Mission IPM’s mission is to prevent HIV transmission by accelerating the development and access of safe and effective microbicides for use by women in developing countries.

  3. 1. Assess and fund across the microbicide portfolio 4. Optimize clinical trial capacity Pre- clinical Clinical trials Launch & Access Basic research Discovery 3. Provide common capabilities or supports for the field 2. Help develop the “next generation” of microbicides 5. Coordinate effort to ensure worldwide access Multiple mechanisms/ targets/products Formulation capacity In vitro and in vivo models Regulatory Manufacturing Pathway of Microbicide Development

  4. IPM Infrastructure • 4 areas of initial focus were on the gaps/bottlenecks in microbicide development pathway: • Screening/activity testing • Formulation • NHP testing • Clinical trials material manufacturing

  5. IPM Clinical Trials • Vaginal ring Phase I trial of TMC120 completed in Belgium • TMC120 Gel Phase I/II trial in Africa (Developing clinical trial sites) • Male tolerance of TMC120

  6. IPM’s Approach to Access • Ensuring availability requires: • Appropriate regulatory approval and licensing infrastructure • Manufacturing capability and sufficient capacity • Logistics and delivery networks in-country • Ensuring adoption requires: • End-user awareness about the product and its benefits • Effective pricing and financing mechanisms to ensure affordability • Supportive social and policy environment (and the research to generate this)

  7. European advocacy activities Aims: • Increase political commitment for microbicides • Increase funding for R&D through national research institutions and PPPs • Advance policy environment for development of, and acess to, microbicides

  8. Canada Denmark EC Gates Foundation Ireland Netherlands Norway Rockefeller Foundation Sweden UK UN US World Bank Current Donors to the IPM

  9. How to Contact IPM? • Visit our website at www.ipm-microbicides.org • Email Tessa Mattholie at: tmattholie@ipm-microbicide.org

More Related